Search Results
Aug 25, 2026, 02:13 ET Keymed Biosciences anuncia los resultados del primer semestre de 2026 y novedades empresariales
2026; el estudio perioperatorio se encuentra en fase II, con planes de expansión a los cánceres biliares y pancreáticos.CM355/PRO-203 (CD20 x CD3), administró la primera dosis a un paciente con esclerosis sistémica en junio e iniciará otros estudios autoinmunes de células B en 2026.CM512
More news about: Keymed Biosciences
Aug 25, 2026, 02:10 ET Keymed Biosciences gibt Ergebnisse für das erste Halbjahr 2026 sowie aktuelle Geschäftsentwicklungen bekannt
Studie befindet sich in der Phase II und wird auf Gallenwegs- und Bauchspeicheldrüsenkrebs ausgeweitet.CM355/PRO-203 (CD20 x CD3): Im Juni wurde der erste SSc-Patient mit dem Medikament behandelt, weitere Studien zu B-Zell-Autoimmunerkrankungen sollen 2026 beginnen.
More news about: Keymed Biosciences
Aug 25, 2026, 02:06 ET Keymed Biosciences annonce ses résultats pour le premier semestre 2026 et fait le point sur ses activités
2026 ; l'étude périopératoire en est à la phase II et s'étend aux cancers des voies biliaires et du pancréas.CM355/PRO-203 (CD20 x CD3) : le premier patient atteint de sclérodermie a reçu son traitement en juin et d'autres études sur les maladies auto-immunes liées aux lymphocytes
More news about: Keymed Biosciences
Aug 24, 2026, 20:30 ET Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases
ATG-201 is a CD19 targeting bispecific TCE incorporating steric hindrance masking technology, designed to eliminate CD19-expressing B cells. This bispecific interaction with T and B cells through CD3 and CD19 has demonstrated potential in treating B cell-driven
More news about: Antengene Corporation Limited
Aug 24, 2026, 19:30 ET Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
needs.ASP2138 is an investigational subcutaneously administered bispecific antibody designed to bind to CLDN18.2, a protein expressed on certain tumor cells, and CD3-positive T cells, a type of white blood cell with the ability to kill cancer cells.1,3 By binding to both targets, ASP2138 is intended to
More news about: Astellas Pharma Inc.
Aug 24, 2026, 15:50 ET The Breed is Back! Commodore to Publish Alien Breed 35th Anniversary Collection for Modern Platforms on September 24
Horror Continues (1993, ECS and AGA versions included), Alien Breed: Tower Assault (1994, Amiga and CD32 versions included), Alien Breed 3D (1995, CD32 version), and Alien Breed 3D II: TKG (1996). Each game is faithful to its original release on the Commodore
More news about: Commodore International Corporation
Aug 24, 2026, 08:00 ET The9 Reports US$32 Million Net Income for Second Quarter of 2026, Up Over 39% Sequentially
https://register-conf.media-server.com/register/BI92e5c045cd54492e95c9c81c36fcf980 All participants must use the link provided above to complete the online registration process in
More news about: The9 Limited
Aug 24, 2026, 05:35 ET European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin
disease control and treatment-related complications³Proof-of-concept trial currently ongoing to evaluate efficacy and safety in Cushing's disease (CD)VALBY, Denmark, Aug. 24, 2026 /PRNewswire/ -- Lundbeck today announced
More news about: H. Lundbeck A/S
Aug 24, 2026, 05:33 ET European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin
disease control and treatment-related complications³Proof-of-concept trial currently ongoing to evaluate efficacy and safety in Cushing's disease (CD)VALBY, Denmark, Aug. 24, 2026 /PRNewswire/ -- Lundbeck today announced
More news about: H. Lundbeck A/S
Aug 23, 2026, 21:00 ET Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D
agreement with UCB for ATG‑201 (CD19 x CD3 T‑cell engager [TCE]) generated a USD 60 million upfront payment. We also entered into an exclusive license agreement with K2 Therapeutics, established by MPM BioImpact, for ATG‑106 (first‑in‑class CDH6 x CD3 TCE), under which the aggregate
More news about: Antengene Corporation Limited
Aug 21, 2026, 08:58 ET Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation, and Accelerating Progress Towards C-MNC
dosing in China. Meanwhile, next-generation innovative molecules with BIC/FIC potential, including HLX3901 (DLL3 x DLL3 x CD3 x CD28 tetra-specific TCE), HLX3902 (STEAP1 x CD3 x CD28 tri-specific TCE), HLX48( c-MET x EGFR bispecific ADC) , HLX97 (small-molecule KAT6A/B inhibitor) and HLX316 (B7-H3 sialidase
More news about: Henlius
Aug 21, 2026, 08:37 ET 復宏漢霖2026年中期業績：盈利能力持續躍升，進入全球價值兌現期
HLX87一線治療HER2陽性乳腺癌的II/III期研究亦持續推進中。Pimurutamab 聯合漢斯狀®及化療一線治療晚期sqNSCLC的II/III期臨床試驗已通過澳大利亞藥品管理局的臨床試驗備案並完成中國首例患者給藥。與此同時，公司高效推進以HLX3901（DLL3 x DLL3 x CD3 x CD28四抗TCE）、HLX3902（STEAP1 x CD3 x CD28三抗TCE）、HLX48（c-MET x EGFR雙抗ADC）、HLX97（KAT6A/B小分子抑制劑）及HLX316（B7-H3唾液酸酶融合蛋白）等為代表的具有BIC/FIC潛力的新一代創新分子，持續夯實長期增長儲備。依托成熟的CMC工藝優勢，公司進一步提高複雜分子成功開
More news about: 復宏漢霖
Aug 21, 2026, 05:20 ET Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World's First Approved 4-1BB-Targeting Therapy
vitro efficacy evaluation, as well as druggability assessment. It has also developed multiple proprietary technology platforms, including LeadsBody (a CD3 T-cell engager platform), X-body (a 4-1BB engager platform), TOPiKinectics (an ADC platform) and ImBiTDC (a TDC platform), which serve as the cornerstone
More news about: Nanjing Leads Biolabs Co., Ltd.
Aug 21, 2026, 05:13 ET Keymed Biosciences Announces 2026 H1 Results and Business Updates
in early 2026; perioperative study is in Phase II, with expansion into biliary and pancreatic cancers.CM355/PRO-203 (CD20 x CD3), dosed first SSc patient in June and will initiate other B‑cell autoimmune studies in 2026.CM512 (TSLP/IL-13 bispecific
More news about: Keymed Biosciences
Aug 21, 2026, 03:24 ET 3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth
antibody): Obtained IND clearances in both China and the U.S. for atopic dermatitis, with Phase I enrollment initiated.In the early-stage pipeline, 717 (CD3/BCMA/CD19 humanized trispecific antibody) for systemic lupus erythematosus/lupus nephritis/rheumatoid arthritis, 718 (anti-TL1A/IL-23 bispecific antibody
More news about: 3SBio Inc.
Aug 21, 2026, 01:40 ET 三生製藥發佈2026中期業績：創新驅動、合作共贏、行穩致遠
610（抗IL-5單抗）成人重度嗜酸性粒細胞哮喘（EA）III期臨床已完成全部受試者入組，青少年重度EA的III期臨床入組中。611（卡泰奇拜單抗）成人中重度特應性皮炎已遞交NDA並獲受理。626（抗BDCA2單抗）系統性紅斑狼瘡和皮膚型紅斑狼瘡II期臨床啟動中；627（抗TL1A單抗）潰瘍性結腸炎II期已啟動入組；716（OX40L/IL-31RA雙抗）特應性皮炎已獲批中美IND，I期臨床已啟動入組。早研管線全方位覆蓋自免適應症，其中717（CD3/BCMA/CD19人源化三特異性抗體）用於系統性紅斑狼
More news about: 三生製藥
Aug 20, 2026, 22:03 ET Charter Announces Expiration And Final Results Of Debt Exchange Offers
$1,250,000,000161175CD4 / US161175CD447
More news about: Charter Communications, Inc.
Aug 20, 2026, 20:00 ET 三生國健發佈2026年半年報：創新驅動・穩健進階
1臨床研究入組。OX40L|IL-31RA雙特異性抗體注射液（研發代碼：716）特應性皮炎適應症已經獲得中美IND的臨床試驗批件並啟動中國健康人I期臨床研究入組。前沿靶點加速轉化，持續深耕自免賽道三生國健通過深入挖掘疾病發生發展的關鍵免疫通路與調控節點，依托結構生物學、AI輔助藥物設計及高通量篩選平台，持續佈局新一代高價值靶點與創新分子類型，已形成雙抗、三抗、口服多肽、吸入抗體等多元化、差異化的產品矩陣。目前創新項目中已有多個進入IND或臨床前關鍵研究階段，其中包括：CD3/BCMA/CD19人源化三特異性抗體注射液（研發代碼：717）、重組抗 TL1A/IL-23雙特異性抗體注射液（研發代碼：718）、TSLP/IL-4R雙特異性抗體吸入劑（研發代碼：719）、I
More news about: 三生製藥
Aug 20, 2026, 20:00 ET Sunshine Guojian Releases 2026 Interim Report:
antibodies, oral peptides, and inhaled antibodies. Multiple innovative programs have now entered the IND or pivotal preclinical study stages, including CD3/BCMA/CD19 humanized trispecific antibody injection (R&D code: 717), recombinant anti-TL1A/IL-23 bispecific antibody injection (R&D code: 718), TSLP/IL-4R
More news about: 3SBio Inc.
Aug 20, 2026, 14:51 ET The CD Rate Forecast Everyone Got Wrong in 2026
offers."About CD ValetCD Valet is a CD marketplace that features verified CD rates from federally insured banks and credit unions. With tens of thousands of CD offers tracked across the country, CD Valet gives savers a clear view of top rates and helps them explore high-yield CD options with
More news about: CD Valet
Aug 20, 2026, 10:09 ET Keymed Biosciences Announces 2026 H1 Results and Business Updates
further differentiated by expanding into additional tumor types, including biliary tract cancer and pancreatic cancer.CM355/PRO-203 (CD20 x CD3 bispecific antibody): Prolium continues to advance an international multi-center Phase I/II clinical study of CM355/PRO-203 for SSc, and
More news about: Keymed Biosciences
Aug 20, 2026, 10:01 ET Agentic AI Market worth $205.88 billion by 2033 - Report by MarketsandMarkets™
exceptions. Vendors serving this segment will need to combine reasoning with secure system access, observability, approval controls, repository and CI/CD integration, and reliable exception handling. As enterprises seek to improve developer productivity, reduce resolution times, automate repetitive support
More news about: MarketsandMarkets
Aug 20, 2026, 09:38 ET C&D Technologies' MSE Pure Lead Technology Receives Gold in 2026 ISE Network Innovators' Awards
content:https://www.prnewswire.com/news-releases/cd-technologies-mse-pure-lead-technology-receives-gold-in-2026-ise-network-innovators-awards-302856490.htmlSOURCE
More news about: C&D Technologies
Aug 20, 2026, 02:22 ET Akiram Therapeutics and ITM Sign Lutetium-177 Supply Agreement to Support Development of AKIR001 for the Treatment of Solid Tumors
177Lu-AKIR001 (AKIR001), a targeted antibody-radionuclide conjugate with first-in-class potential, currently in clinical testing for the treatment of CD44v6-expressing solid tumors.UPPSALA, Sweden and MUNICH and GARCHING, Germany, August
More news about: Akiram Therapeutics
Aug 19, 2026, 10:31 ET Checkpoint Inhibitor Refractory Cancer Market Outlook is Predicted to Improve by 2036, Biopharma Companies Advance Novel Immuno-Oncology Candidates | DelveInsight
tumors that have become resistant to checkpoint blockade.ImCheck Therapeutics' ICT01 is a humanized monoclonal antibody targeting BTN3A (CD277) that selectively activates γ9δ2 T cells, key immune cells involved in the surveillance and elimination of malignant and infected cells. The three BTN3A
More news about: DelveInsight Business Research, LLP